Headquarters: Cambridge, MA, United States
Founded: September 2010
CEO: Mr. Stephane Bancel
USD as of July 1, 2023
Moderna, Inc. is a biotechnology company, specialized in vaccine technology based on messenger RNA. It is notably famous for producing one of the first vaccines against Covid-19, and it is also developing and patenting other vaccine candidates for seasonal flu, HIV, the Nipah virus, and a second COVID-19 vaccine.
|Company||Market Cap (USD)|
|Novo Nordisk||$329.83 B|
|Vertex Pharmaceuticals Incorporated||$88.79 B|
|CSL Limited||$85.00 B|
|Marinomed Biotech AG||$84.73 B|
|Regeneron Pharmaceuticals, Inc.||$78.88 B|
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Unlock the Power of Financial AI:
Try Disfold AI Free for 7 Days!
Moderna, Inc. has the following listings and related stock indices.
Moderna COVID-19 vaccine
Founder(s): Derrick Rossi Timothy A. Springer Robert S. Langer Kenneth R. Chien Noubar Afeyan
Stéphane Bancel, CEO Stephen Hoge, President David Meline, CFO Noubar Afeyan, Chairman Robert S. Langer, Director Paul Sagan, Director
Revenue: US$18.5 billion (2021)
Operating income: US$13.3 billion (2021)
Net income: US$12.2 billion (2021)
Total assets: US$24.7 billion (2021)
Total equity: US$24.7 billion (2021)